CGON
Price
$55.43
Change
+$2.85 (+5.42%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
4.24B
72 days until earnings call
Intraday BUY SELL Signals
SYRE
Price
$33.17
Change
+$1.64 (+5.20%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
2.45B
43 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CGON vs SYRE

Header iconCGON vs SYRE Comparison
Open Charts CGON vs SYREBanner chart's image
CG Oncology
Price$55.43
Change+$2.85 (+5.42%)
Volume$12.84K
Capitalization4.24B
Spyre Therapeutics
Price$33.17
Change+$1.64 (+5.20%)
Volume$6.9K
Capitalization2.45B
CGON vs SYRE Comparison Chart in %
CGON
Daily Signal:
Gain/Loss:
SYRE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CGON vs. SYRE commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGON is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (CGON: $52.58 vs. SYRE: $31.53)
Brand notoriety: CGON and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGON: 94% vs. SYRE: 89%
Market capitalization -- CGON: $4.24B vs. SYRE: $2.45B
CGON [@Biotechnology] is valued at $4.24B. SYRE’s [@Biotechnology] market capitalization is $2.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $115.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGON’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • CGON’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, both CGON and SYRE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGON’s TA Score shows that 6 TA indicator(s) are bullish while SYRE’s TA Score has 3 bullish TA indicator(s).

  • CGON’s TA Score: 6 bullish, 4 bearish.
  • SYRE’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CGON is a better buy in the short-term than SYRE.

Price Growth

CGON (@Biotechnology) experienced а +30.25% price change this week, while SYRE (@Biotechnology) price change was +3.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

CGON is expected to report earnings on Mar 27, 2026.

SYRE is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGON($4.24B) has a higher market cap than SYRE($2.45B). CGON YTD gains are higher at: 26.638 vs. SYRE (-3.755). CGON has higher annual earnings (EBITDA): -179.53M vs. SYRE (-223.64M). CGON has more cash in the bank: 680M vs. SYRE (486M). SYRE has less debt than CGON: SYRE (0) vs CGON (7.24M). CGON has higher revenues than SYRE: CGON (2.17M) vs SYRE (0).
CGONSYRECGON / SYRE
Capitalization4.24B2.45B173%
EBITDA-179.53M-223.64M80%
Gain YTD26.638-3.755-709%
P/E RatioN/A1.72-
Revenue2.17M0-
Total Cash680M486M140%
Total Debt7.24M0-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
54
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
82
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CGONSYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 8 days ago
76%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 10 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CGON
Daily Signal:
Gain/Loss:
SYRE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
YAFIX20.020.22
+1.11%
AMG Yacktman Focused I
ATGYX48.800.21
+0.43%
Cantor Fitzgerald Equity Opp Inst
MRSGX24.49-0.08
-0.33%
MFS Research International R1
EISAX32.72-0.12
-0.37%
Carillon ClariVest Intl Stock A
APDLX14.72-0.10
-0.67%
Artisan Value Advisor

CGON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGON has been loosely correlated with RVMD. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if CGON jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGON
1D Price
Change %
CGON100%
-2.12%
RVMD - CGON
54%
Loosely correlated
+2.37%
NUVL - CGON
53%
Loosely correlated
+2.03%
SYRE - CGON
53%
Loosely correlated
-3.87%
IDYA - CGON
52%
Loosely correlated
-4.75%
XNCR - CGON
51%
Loosely correlated
-1.62%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with ORKA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then ORKA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-3.87%
ORKA - SYRE
58%
Loosely correlated
+2.12%
BEAM - SYRE
57%
Loosely correlated
+2.55%
XNCR - SYRE
57%
Loosely correlated
-1.62%
RGNX - SYRE
57%
Loosely correlated
-0.20%
APGE - SYRE
55%
Loosely correlated
+1.74%
More